Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis

Trial Profile

Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tapinarof (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 26 May 2020 Results presented in the Dermavant Sciences Media Release.
  • 12 May 2020 Results assessing secondary Efficacy and patient-reported Outcomes, published in the Journal of the American Academy of Dermatology
  • 21 Feb 2019 According to a Dermavant Sciences media release, data from this study will be presented in a poster format and an oral presentation at the 2019 American Academy of Dermatology (AAD) Annual Meeting (March 1-5, 2019).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top